First-In-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR In Patients With Advanced Cancer

PURPOSE: To evaluate safety (primary endpoint), tolerability, pharmacokinetics, pharmacodynamic profile, and preliminary activity of the intravenous, pan-class I isoform PI3K/mTOR inhibitor PF-05212384 in patients with advanced solid tumors. EXPERIMENTAL DESIGN: Part 1 of this open-label phase I stu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Shapiro, Geoffrey I., Bell-McGuinn, Katherine M., Molina, Julian R., Bendell, Johanna C., Spicer, James, Kwak, Eunice L., Pandya, Susan, Millham, Robert, Borzillo, Gary, Pierce, Kristen, Han, Lixin, Houk, Brett, Gallo, Jorge D., Alsina, Maria, Braña, Irene, Tabernero, Josep
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4508327/
https://ncbi.nlm.nih.gov/pubmed/25652454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1306
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados